参考文献/References:
［1］ 魏秋红,刘晓月,王盼,张文锐.抗肿瘤药物的分类和药效学研究进展［J］.医学综述,2020,26(18):3707-3711,3716.
WEI Q H,LIU X Y,WANG P,ZHANG W R.Research progress in classification and pharmacodynamics of anti-tumor drugs［J］.Med Recapitulate,2020,26(18):3707-3711,3716.
［2］ LI J,TRIPATHI R C,TRIPATHI B J.Drug-induced ocular disorders［J］.Drug Saf,2008，31(2):127-141.
［3］ HO W L,WONG H,YAU T.The ophthalmological complications of targeted agents in cancer therapy:what do we need to know as ophthalmologists［J］.Acta Ophthalmol,2013，91(7):604-609.
［4］ JABLONSKI S A,LIU S T,YEN T J.Targeting the kinetochore for mitosis-specific inhibitors［J］.Cancer Biol Ther,2003,2(3):236-241.
［5］ SMITH J A,SLUSHER B S,WOZNIAK K M,FARAH M H,SMIYUN G,WILSON L,et al.Structural basis for induction of peripheral neuropathy by microtubule-targeting cancer drugs［J］.Cancer Res,2016,76(17):5115-5123.
［6］ MINOTTI G,MENNA P,SALVATORELLI E,CAIRO G,GIANNI L.Anthracyclines:molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity［J］.Pharmacol Rev,2004,56(2):185-229.
［7］ MAMOUNAS E P,BANDOS H,LEMBERSKY B C,JEONG J H,GEYER C E JR,RASTOGI P,et al.Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42):a randomised,double-blind,placebo-controlled,phase 3 trial［J］.Lancet Oncol,2019,20(1):88-99.
［8］ 顿耀军,刘春雷,陈黎黎,张晓威,于路平,李清，等.前列腺癌患者单纯雄激素去除治疗后健康相关生活质量的评估［J］.中华泌尿外科杂志,2017,38(1):33-37.
DUN Y J,LIU C L,CHEN L L,ZHANG X W,YU L P,LI Q,et al.Assessment of health-related quality of life in patients with prostate cancer after androgen deprivation therapy alone［J］.Chin J Urology,2017,38(1):33-37.
［9］ 邵毅,周琼.糖尿病视网膜病变诊治规范——2018年美国眼科学会临床指南解读［J］.眼科新进展,2019,39(6):501-506.
SHAO Y,ZHOU Q.Interpretation of clinical guidelines for diabetic retinopathy of the American Academy of Ophthalmology 2018［J］.Rec Adv Ophthalmol,2019,39(6):501-506.
［10］ GERBER D E.Targeted therapies:a new generation of cancer treatments［J］.Am Fam Physician,2008,77(3):311-319.
［11］ 迟来婷,曲利军.药物的眼表损害［J］.中国中医眼科杂志,2014,24(4):304-308.
CHI L T,QU L J.Drug induced ocular surface damage ［J］.Chin J Ophthalmol,2014,24(4):304-308.
［12］ DONG F,CALL M,XIA Y,KAO W W.Role of EGF receptor signaling on morphogenesis of eyelid and meibomian glands［J］.Exp Eye Res,2017,163:58-63.
［13］ TUCKER S M,LINBERG J V.Vascular anatomy of the eyelids［J］.Ophthalmology,1994,101(6):1118-1121.
［14］ SCHLEMMER M,BAUER S,SCHUTTE R,HARTMANN J T,BOKEMEYER C,HOSIUS C,et al.Activity and side effects of imatinib in patients with gastrointestinal stromal tumors:data from a German multicenter trial［J］.Eur J Med Res,2011,16(5):206-212.
［15］ FRAUNFELDER F T,FRAUNFELDER F W.Oral anti-vascular endothelial growth factor drugs and ocular adverse events［J］.J Ocul Pharmacol Ther,2018,34(6):432-435.
［16］ SCHALLIER D,DECOSTER L,FONTAINE C,DE GREVE J.Pemetrexed-induced eyelid edema:incidence and clinical manifestations［J］.Anticancer Res,2010,30(12):5185-5188.
［17］ PIETRAS K,OSTMAN A,SJOQUIST M,BUCHDUNGER E,REED R K,HELDIN C H,et al.Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors［J］.Cancer Res,2001,61(7):2929-2934.
［18］ METHVIN A B,GAUSAS R E.Newly recognized ocular side effects of erlotinib［J］.Ophthalmic Plast Reconstr Surg,2007,23(1):63-65.
［19］ KARAMITSOS A,KOKKAS V,GOULAS A,PARASKEVOPOULOS P,GOUGOULIAS K,KARAMPATAKIS V,et al.Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil,Epirubicin and Cyclophosphamide (FEC) regimen［J］.Hippokratia,2013,17(2):120-125.
［20］ MELICHAR B,NEMCOVA I.Eye complications of cetuximab therapy［J］.Eur J Cancer Care (Engl),2007,16(5):439-443.
［21］ HO W L,WONG H,YAU T.The ophthalmological complications of targeted agents in cancer therapy:what do we need to know as ophthalmologists［J］.Acta Ophthalmol,2013,91(7):604-609.
［22］ ESMER O,KARADAG R,SOYLU E,ONER A F,BURAKGAZI-DALKILIC E.Nasolacrimal system obstruction,ptosis and esotropia due to chemotherapy in acute lymphoblastic leukemia［J］.Cutan Ocul Toxicol,2013,32(4):330-332.
［23］ PALKAR A H,NAIR A G,DESAI R J,POTDAR N A,SHINDE C A.Vincristine-induced neuropathy presenting as ptosis and ophthalmoplegia in a 2-year-old boy［J］.J Pediatr Ophthalmol Strabismus,2015,52:e34-e37.
［24］ MAKARIOUS D,HORWOOD K,COWARD J I G.Myasthenia gravis:an emerging toxicity of immune checkpoint inhibitors［J］.Eur J Cancer,2017,82:128-136.
［25］ CRESPO-CARBALLES M J,GARCIA-SAENZ M C,GONZALEZ-SOSA Z C,PRIETO-DEL-CURA M.Trichomegaly induced by cetuximab［J］.J Fr Ophtalmol,2020,43(9):958-960.
［26］ GOYAL A,BLAES A.Trichomegaly associated with panitumumab［J］.N Engl J Med,2020,383(16):e94.
［27］ ALEXANDRESCU D T,KAUFFMAN C L,DASANU C A.Persistent hair growth during treatment with the EGFR inhibitor erlotinib［J］.Dermatol Online J,2009,15(3):4.
［28］ BORKAR D S,LACOUTURE M E,BASTI S.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up:a five-year review［J］.Support Care Cancer,2013,21(4):1167-1174.
［29］ DUNNILL C J,AL-TAMEEMI W,COLLETT A,HASLAM I S,GEORGOPOULOS N T.A clinical and biological guide for understanding chemotherapy-induced alopecia and its prevention［J］.Oncologist,2018,23(1):84-96.
［30］ GARIBALDI D C,ADLER R A.Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab［J］.Ophthalmic Plast Reconstr Surg,2007,23(1):62-63.
［31］ MANSUR C,PDEIFFER M L,ESMAELI B.Evaluation and management of chemotherapy-induced epiphora,punctal and canalicular stenosis,and nasolacrimal duct obstruction［J］.Ophthalmic Plast Reconstr Surg,2017,33(1):9-12.
［32］ MATAUMOTO Y,DOGRU M,SATO E A,IBRAHIM O M,TATEMATSU Y,OGAWA Y,et al.S-1 induces meibomian gland dysfunction［J］.Ophthalmology,2010,117(6):1275,e4-e7.
［33］ ESMAELI B,DIBA R,AHMADI M A,SAADATI H G,FAUSTINA M M,SHEPLER T R,et al.Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)［J］.Eye (Lond),2004,18(7):760-762.
［34］ RADAELLI F,VENER C,RIPAMONTI F,IURLO A,COLOMBI M,ARTONI A,et al.Conjunctival hemorrhagic events associated with imatinib mesylate［J］.Int J Hematol,2007,86(5):390-393.
［35］ LOCHHEAD J,SALMIN J F,BRON A J.Cytarabine-induced corneal toxicity［J］.Eye (Lond),2003,17(5):677-678.
［36］ MARTIN M,VILLAR A,SOLE-CALVO A,GONZALEZ R,MASSUTI B,LIZON J,et al.Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v.FAC regimen,day 1,21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v.CMF regimen,day 1,21) as adjuvant chemotherapy for operable breast cancer:a study by the GEICAM group［J］.Ann Oncol,2003,14(6):833-842.
［37］ AGUSTONI F,PLATANIA M,VITALI M,ZILEMBO N,HASPINGER E,SINNO V,et al.Emerging toxicities in the treatment of non-small cell lung cancer:ocular disorders［J］.Cancer Treat Rev,2014,40(1):197-203.
［38］ STEELE W H,STUART J F,WHITING B,LAWRENCE J R,CALMAN K C,MCVIE J G,et al.Serum,tear and salivary concentrations of methotrexate in man［J］.Br J Clin Pharmacol,1979,7(2):207-211.
［39］ ESMAELI B,AHMADI M A,RIVERA E,VALERO V,HUTTO T,JACKSON D M,et al.Docetaxel secretion in tears:association with lacrimal drainage obstruction［J］.Arch Ophthalmol,2002,120(9):1180-1182.
［40］ SKOLNICK C A,DOUGHMAN D J.Erosive conjunctivitis and punctal stenosis secondary to docetaxel (taxotere)［J］.Eye Contact Lens,2003,29(2):134-135.
［41］ BORKAR D S,LACOUTURE M E,BASTI S.Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up:a five-year review［J］.Support Care Cancer,2013,21(4):1167-1174.
［42］ TSUDA M,TAKANO Y,SHIGEYASU C,IMOTO S,YAMADA M.Abnormal corneal lesions induced by trastuzumab emtansine:an antibody-drug conjugate for breast cancer［J］.Cornea,2016,35(10):1378-1380.
［43］ KANIE S,FUJIEDA M,HITOTSUMACHI T,SUZUKI S,MORITA F,HAKOI K,et al.Alleviating effects of artificial tear instillation on S-1-induced ocular toxicity in dogs［J］.J Toxicol Sci,2017,42(3):291-300.
［44］ SAINT-JEAN A,SAINZ DE LA MAZA M,MORRAL M,TORRAS J,QUINTANA R,MOLINA J J,et al.Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor:report of 5 cases［J］.Ophthalmology,2012,119(9):1798-1802.
［45］ IOVIENO A,LAMBIASE A,MORETTI C,PERRELLA E,BONINI S.Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression［J］.Cornea,2009,28(7):821-824.
［46］ GARRANA R M,ZIESKE J D,ASSOULINE M,GIPSON I K.Matrix metalloproteinases in epithelia from human recurrent corneal erosion［J］.Invest Ophthalmol Vis Sci,1999,40(6):1266-1270..
［47］ AKUNE Y,YAMADA M,SHIGEYASU C.Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent,S-1［J］.Jpn J Ophthalmol,2018,62(4):432-437.
［48］ LOPRINZI C L,LOVE R R,GARRITY J A,AMES M M.Cyclophosphamide,methotrexate,and 5-fluorouracil (CMF)-induced ocular toxicity［J］.Cancer Invest,1990,8(5):459-465.
［49］ WAIKHOM B,FRAUNFELDER F T,HENNER W D.Severe ocular irritation and corneal deposits associated with capecitabine use［J］.N Engl J Med,2000,343(10):740-741.
［50］ ZINCHUK O,WATANABE M,HAYASHI N,FUKUSHIMA A,UENO H.A case of tamoxifen keratopathy［J］.Arch Ophthalmol,2006,124(7):1046-1048.
［51］ YEH S,FINE H A,SMITH J A.Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma［J］.Cornea,2009,28(6):699-702.
［52］ AHN J,WEE W R,LEE J H,HYON J Y.Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer［J］.Korean J Ophthalmol,2011,25(5):355-357.
［53］ CHIA P L,JOHN T.Vortex keratopathy presumed secondary to AZD9291［J］.J Thorac Oncol,2015,10(12):1807-1808.
［54］ CAPPELLI L C,GUTIERREZ A K,BAER A N,ALBAYDA J,MANNO R L,HAQUE U,et al.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab［J］.Ann Rheum Dis,2017,76(1):43-50.
［55］ WARNER B M,BAER A N,LIPSON E J,ALLEN C,HINRICHS C,RAJAN A,et al.Sicca syndrome associated with immune checkpoint inhibitor therapy［J］.Oncologist,2019,24(9):1259-1269.
［56］ ABDEL-RAHMAN O,OWEIRA H,PETRAUSCH U,HELBLING D,SCHMIDT J,MANNHART M,et al.Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors:a systematic review［J］.Expert Rev Anticancer Ther,2017,17(4):387-394.
［57］ AZKARGORTA M,SORIA J,ACERA A,ILORO I,ELORZA F.Human tear proteomics and peptidomics in ophthalmology:toward the translation of proteomic biomarkers into clinical practice［J］.J Proteomics,2017,150:359-367.
［58］ CHATZIRALLI I,SERGENTANIS T,ZAGOURI F,CHRYSIKOS D,LADAS I,ZOGRAFOS G C,et al.Ocular surface disease in breast cancer patients using aromatase inhibitors［J］.Breast J,2016,22(5):561-563.
［59］ YANG Q C,BAO J,LI C,TAN G,WU A H,YE L,et al.A murine model of dry eye induced by topical administration of erlotinib eye drops［J］.Int J Mol Med,2018,41(3):1427-1436.
［60］ KIM S,YOO Y S,KIM H S,JOO C K,NA K S.Changes of meibomian glands in the early stage of post hematopoietic stem cell transplantation［J］.Exp Eye Res,2017,163:85-90.
［61］ GIANNACCARE G,BONIFAZI F,SESSA M,FRESINA M,ARPINATI M,BANDINI G,et al.Dry eye disease is already present in hematological patients before hematopoietic stem cell transplantation［J］.Cornea,2016,35(5):638-643.
［62］ GIANNACCARE G,BONIFAZI F,SEBASTIANI S,SESSA M,PELLEGRINI M,ARPINATI M,et al.Meibomian gland dropout in hematological patients before hematopoietic stem cell transplantation［J］.Cornea,2018,37(10):1264-1269.
［63］ KIM N,KIM J W,BAEK J H,KIM J S,CHOUNG H K,KIM T Y,et al.S-1-induced lacrimal drainage obstruction and its association with ingredients/metabolites of S-1 in tears and plasma:a prospective multi-institutional study［J］.Cancer Res Treat,2018,50(1):30-39.
［64］ BASKIN Y,AMIRFALLAH A,UNAL O U,CALIBASI G,OZTOP I.Dihydropyrimidine dehydrogenase 85T>C mutation is associated with ocular toxicity of 5-fluorouracil:a case report［J］.Am J Ther,2015,22(2):e36-e39.
［65］ HOLLANDER D A,ALDAVE A J.Drug-induced corneal complications［J］.Curr Opin Ophthalmol,2004,15(6):541-548.（下转第81页）